Objective To analyze the efficacy of diabetes mellitus combined with heart failure treated with dapa-gliflozin combined with metoprolol extended-release tablets.Methods A total of 76 patients with diabetes mellitus combined with heart failure in Jingjiang Second People's Hospital from January 2021 to October 2023 were selected as the study objects,and were divided into two groups of 38 patients each according to the randomized table method.The control group was treated with metoprolol extended-release tablets,and the study group was treated with com-bined dapagliflozin,and blood glucose,cardiac function and adverse reactions were observed in both groups.Results Before treatment,there was no statistically significant difference in blood glucose indexs between the two groups(all P>0.05).After treatment,the fasting plasma glucose,2-hour postprandial blood glucose and glycated hemoglobin of the study group were(7.54±1.12)mmol/L,(10.01±2.52)mmol/L,and(6.54±2.13)%,respectively,which were better than those of the control group(8.63±1.15)mmol/L,(12.82±4.15)mmol/L,and(7.88±2.17)%,and the differences were sig-nificantly significant(t=4.186,3.568,2.717,all P<0.05).Before treatment,there was no statistically significant differ-ence in cardiac function indexes between the two groups(all P>0.05).After treatment,the cardiac function indexes of the study group were better than those of the control group,and the differences were significantly significant(all P<0.05).The incidence of adverse reactions in the study group(10.53%)was higher than that in the control group(5.26%),and the difference was not significantly significant(χ2=0.181,P>0.05).Conclusion Diabetes mellitus com-bined with heart failure is better treated with dapagliflozin combined with metoprolol,which not only stabilizes blood glucose,but also relieves the abnormal state of cardiac function,and has less adverse reactions and higher safety.
DapagliflozinMetoprolol extended-release tabletsDiabetes mellitusHeart failureCardiac function
NETL
NSTL
万方数据
